Tepha raises $4.3m for biomaterial development:
This article was originally published in Clinica
Tepha, a private developer of medical devices used in surgical repair and regenerative medicine, has secured $4.3m in financing from The Vertical Group, Integra Ventures and Novartis Venture Fund. The Cambridge, Massachusetts-based company says it will use the proceeds to complete FDA 510(k) filings for its debut range of TephaFLEX products. TephaFLEX, a polyester biomaterial made from a natural metabolite and which degrades "in a cell-friendly manner", is currently being developed by Tepha for several applications including suture, surgical mesh and patch products, tissue repair and tissue engineered cardiovascular devices.